Abstract:Objective To analyze the clinical characteristics,survival,and prognosis of the patients with different molecular subtypes of breast cancer.Methods Clinical data of 304 patients with histopathologically confirmed resectable breast cancer,treated in the 1st Affiliated Hospital of Kunming Medical University from Feb.2002 to Feb.2004,were collected and analyzed in this study.ER,PR and HER-2 in all the excised tissues were determined by immunohistochemistry,and according to the results,the patients were divided into luminal,HER-2 and triple-negative breast cancer.The clinical characteristics,recurrence and survival of the patients with different subtypes of breast cancer were analyzed.Results In this study,luminal,HER-2 and triple-negative breast cancer accounted for 53.0%,20.4% and 26.6%,and the median age of patients with the three subtypes was 50.8,50.3and 47.1,respectively.Histological grade of luminal type was lower than other subgroup of breast cancer.The percentage of luminal type with histological grade I was 43.1%.HER-2 type was commonly seen in premenopausal women(66.1%),its histological grade was between luminal and triple-negative type.Triple-negative breast cancer was more likely to be found in younger patients frequently with a familial history of breast cancer(9.9%).Histological grade of triple-negative breast cancer was higher than other groups.The percentage of triple-negative patients with histological grade III was 49.0%.Among the three type patients,there was no significant difference in menopausal status,tumor stage,pathologic types and lymph node metastasis.By Feb.2009,the median time of follow-up was 71 months(60～84 months).Patients with HER-2 or triple-negative breast cancer were found to have a significantly higher recurrence and metastasis rate than the patients with luminal type breast cancer,but no significant difference was observed between triple-negative and HER-2 types.HER-2 type patients were more likely to develop bone metastases than triple-negative patients(46.7% vs 13.3%,P0.05),and triple-negative patients were more likely to develop lung metastases than HER-2 patients(46.7% vs 20.3%,P0.05).Up to February 2009,the 5-year disease-free rates(DFS)for patients with Luminal,HER-2 and triple-negative types were 90.1%,75.8% and 76.5%(P0.05),respectively.The overall 5-year survival rates(OS)of the three groups were 96.9%,85.5% and 87.7%(P0.05),respectively.Conclusion Patients with different subtype of breast cancer have different clinical characteristics,recurrence pattern and prognosis.

[Survival Analysis for Different Molecular Subtypes of Breast Cancers after Treatment].

Clinical Characteristics and Prognosis of Different Subtypes of Breast Cancer

Differences in Breast Cancer Survival by Molecular Subtypes in the United States

Pathological features and prognosis of different molecular subtypes of breast cancer

Molecular Subtype Approximated by Quantitative Estrogen Receptor, Progesterone Receptor and Her2 Can Predict the Prognosis of Breast Cancer

Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up

[Relationship Between Breast Cancer Molecular Subtypes with Clinicopathological Characteristics and Prognosis].

Association of molecular subtypes and treatment with survival in invasive micropapillary breast cancer: an analysis of the Surveillance, Epidemiology, and End Results database

Clinical Characteristics and Survival Analysis of Breast Cancer Molecular Subtypes with Hepatic Metastases

Different Breast Cancer Subtypes Show Different Metastatic Patterns: A Study from A Large Public Database

A Study on the Relationship Between Breast Cancer Molecular Classification and Prognosis

Clinical significance of four subtypes of breast cancer

Clinicopathological characteristics and survival analysis of different molecular subtypes of breast invasive ductal carcinoma achieving pathological complete response through neoadjuvant chemotherapy

An Analysis of Clinical Features and Survival for Brain Metastases in Different Subtypes of Breast Cancer

Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients.

Survival following radiotherapy in young women with localized early-stage breast cancer according to molecular subtypes.

Breast Cancer Subtypes and Survival in Chinese Women with Operable Primary Breast Cancer

Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data

Molecular Subtype Can Predict the Response and Outcome of Chinese Locally Advanced Breast Cancer Patients Treated with Preoperative Therapy

Combination Impact Of Axillary Lymph Node Status And Biological Subtypes On Prognosis And Breast Conserving Surgery In Locally-Invasive Breast Cancer: A Real-World Study Of A Chinese Population